ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rituximab

Also written as “rituximab”, “rituximab [MabThera/Rituxan]” and “Rituximab SC”.

Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Leukemia, Lymphocytic, Chronic, B-Cell, led by 20 companies.

Drug pageRituximab: every studyMany companies study it; this page follows only the 124 they lead. All 1,284 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 18, 2007124 company-led studies, 6 open or runningNext primary completion: Oct 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only781 open or runningphase 4since Jan 18, 2007Apr 1, 2003none ahead
SymBio Pharmaceuticals50 open or runningphase 3since Dec 10, 2017Nov 18, 2008none ahead
AbbVieits history only40 open or runningphase 3since Jun 9, 2014Apr 20, 2012none ahead
AstraZenecaits history only42 open or runningphase 4since Aug 23, 2023Apr 8, 2016Oct 31, 2028phase 2 · NCT05951959
Biogenits history only40 open or runningphase 4since Aug 23, 2004Mar 31, 2003none ahead
Takedaits history only40 open or runningphase 3since Apr 7, 2006Jun 11, 2004none ahead
Biocadits history only30 open or runningphase 3since Oct 3, 2012Oct 3, 2012none ahead
Celltrionits history only30 open or runningphase 1since Feb 8, 2012Feb 8, 2012none ahead
Favrilleits history only30 open or runningphase 3since Aug 4, 2004Aug 4, 2004none ahead
GlaxoSmithKlineits history only20 open or runningphase 3since Oct 13, 2017Dec 14, 2015none ahead

Also a collaborator on its studies: ICON Clinical Research, Johnson & Johnson, Bristol-Myers Squibb, Merck KGaA, Darmstadt, Germany, UCB, Eli Lilly, Teva Pharmaceutical Industries, Roche Pharma and Chiron.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of SymBio Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 18, 2008First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT00794638 · 9 enrolled · Japan
  2. May 1, 2010Phase 2 study in Lymphoma, Non-HodgkinNCT01118845 · 63 enrolled · Japan, Korea, Republic of
  3. Oct 29, 2012Phase 2 study in Low-grade B Cell Non-Hodgkin's LymphomaNCT01718691 · 70 enrolled · Japan
  4. Dec 10, 2017Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT03372837 · 40 enrolled · Japan
  5. Mar 6, 2019Phase 2 study in LymphomaNCT03900377 · 37 enrolled · Japan
  6. Jan 29, 2026Named rituximabINNProposed as its International Nonproprietary Name in WHO's List 134 · before, MK-8808

TargetBeta

MS4A1 →read by rule
“A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
ocrelizumabruleHoffmann-La Rochephase 442
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

All 5 SymBio Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03900377Lymphoma · Japan2CompletedSep 9, 202037
NCT03372837Lymphoma, Large B-Cell, Diffuse · Japan3CompletedDec 31, 201940
NCT01718691Low-grade B Cell Non-Hodgkin's Lymphoma · Japan2CompletedNov 201370
NCT01118845Lymphoma, Non-Hodgkin · Japan, Korea, Republic of2CompletedOct 201163
NCT00794638Lymphoma, Non-Hodgkin · Japan1CompletedMar 20109

How it is read

Names in the registry

  • “Rituximab”, 104 entries
  • “rituximab”, 34 entries
  • “rituximab [MabThera/Rituxan]”, 23 entries
  • “Rituximab SC”, 2 entries
  • “MK-8808”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.